Multimodal global specialty pharma CDMO OneSource launches at CPHI Milan
09 October 2024 | News
OneSource is currently undergoing regulatory approvals and, upon completion, will be listed on the India stock exchanges
image credit- shutterstock
OneSource Specialty Pharma, a newly incorporated contract development and manufacturing organisation (CDMO), formed from the merger of three CDMO businesses within the Strides Group launches at CPHI Milan.
OneSource is strategically positioned, with the remarkable growth of GLP-1s and the BIOSECURE Act, to address the increasing demand for drug-device combinations and biologics drug substances and product.
The newly combined CDMO has five world-class facilities approved by major regulatory agencies, including the US FDA, EU, and TGA, with a workforce of over 1,200 professionals.
OneSource has capabilities spanning supply-constrained drug-device combinations, biologics, and soft gelatin capsules – with the capacity to produce more than 100 million injectable doses including cartridges and pre-filled-syringes and 2.4 billion soft gelatin capsules. Notably, its flagship site in Bengaluru is one of the few globally capable of manufacturing both biologics drug substance and drug product on the same premises.
The company’s end-to-end offering across all its platforms was established in response to its customers’ need to streamline supply chains by consolidating their outsourcing partners. The three combined businesses, each serve over 50 global clients, and together reduce complexity, cost, and resources associated with managing multiple CDMO service providers.
OneSource is projected to achieve a remarkable 32% revenue growth in 2025, with sales anticipated to reach $400 million by 2028.
